{"title":"Current Clinical Utility of Circulating Tumor DNA Testing in Breast Cancer: A Practical Approach.","authors":"Jing Xi, Cynthia X Ma, Joyce O'Shaughnessy","doi":"10.1200/OP.24.00274","DOIUrl":null,"url":null,"abstract":"<p><p>Circulating tumor DNA (ctDNA) refers to DNA fragments released from cancer cells into the bloodstream. Clinical utility of ctDNA in breast cancer has been explored in both metastatic breast cancer (MBC) and early-stage breast cancer (EBC) settings. In MBC, ctDNA can detect therapeutically targetable genomic alterations and has shown great potential in predicting treatment response or resistance. Accumulating data suggest that ctDNA might also have prognostic value in MBC. In EBC, emerging data have shown ctDNA's predictive and/or prognostic value in both neoadjuvant and adjuvant settings. Minimal residual disease (MRD) detection via ctDNA to detect clinical recurrence after curative therapy is a rapidly advancing field. In this review, we discuss the existing and emerging data regarding ctDNA utility in both MBC and EBC settings.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":"20 11","pages":"1460-1470"},"PeriodicalIF":4.7000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO oncology practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/OP.24.00274","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Circulating tumor DNA (ctDNA) refers to DNA fragments released from cancer cells into the bloodstream. Clinical utility of ctDNA in breast cancer has been explored in both metastatic breast cancer (MBC) and early-stage breast cancer (EBC) settings. In MBC, ctDNA can detect therapeutically targetable genomic alterations and has shown great potential in predicting treatment response or resistance. Accumulating data suggest that ctDNA might also have prognostic value in MBC. In EBC, emerging data have shown ctDNA's predictive and/or prognostic value in both neoadjuvant and adjuvant settings. Minimal residual disease (MRD) detection via ctDNA to detect clinical recurrence after curative therapy is a rapidly advancing field. In this review, we discuss the existing and emerging data regarding ctDNA utility in both MBC and EBC settings.
循环肿瘤 DNA（ctDNA）是指从癌细胞释放到血液中的 DNA 片段。ctDNA在乳腺癌中的临床应用已在转移性乳腺癌（MBC）和早期乳腺癌（EBC）中进行了探索。在 MBC 中，ctDNA 可以检测出治疗上可靶向的基因组改变，并在预测治疗反应或耐药性方面显示出巨大的潜力。不断积累的数据表明，ctDNA 在 MBC 中也可能具有预后价值。在 EBC 中，新出现的数据显示了 ctDNA 在新辅助治疗和辅助治疗中的预测和/或预后价值。通过ctDNA检测最小残留病（MRD）以发现治愈性治疗后的临床复发是一个进展迅速的领域。在这篇综述中，我们将讨论有关ctDNA在MBC和EBC治疗中的作用的现有和新出现的数据。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
